Rise and shine, everyone, another busy day is on the way. We can tell because our shortest person dashed for the local schoolhouse, a leading indicator that there is much to be done, no matter your standing. So this means, of course, that we must once again fire up the coffee kettle and brew some cups of stimulation. This is a ritual, you know, and today we are reaching for cinnamon swirl. Please feel free to join us or, if you prefer, grab a bottle of water. Meanwhile, speaking of busy, here are some tidbits. Hope you have a smashing day …

A critical drug that serves as the backbone of treatment for most childhood cancers, including leukemias, lymphomas, and brain tumors, has become increasingly scarce, and doctors are warning that they may soon be forced to consider rationing doses, The New York Times tells us. Persistent shortages of certain drugs and medical supplies have plagued the U.S. for years, but physicians say the loss of this medication, vincristine, is uniquely problematic, as there is no appropriate substitute.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy